Other

Vironova Influenza Ab

Vironova Thionation Ab

Oxypharma Ab

Leif J. I. Lundblad

Asea Brown Boveri Ab

Vironova Herpes Ab

Vironova Ab

Jan Bergman

Mohammed Homman

Lennart M&ouml;ller

Bengt Gerdin

Birgitta Pettersson

Vedran Hasimbegovic

Robert Berg

Ingemar Kihlström

Per H Svensson

Ulf Björklund

Ngarita Kingi

Robert Engovist

Hans Vallberg

Lennart Johansson

Cecilia E Söderberg-Nauclér

Robert Engqvist

Cecilia Söderberg-Nauclér

A pharmaceutical composition for topical administration including 2,3-dimethyl-6-(N,N-dimethylaminoethyl)-6H-indolo-(2,3-b)quinoxaline(B-220) or a pharmaceutically acceptable salt thereof in a pharmaceutically acceptable carrier The composition is useful for the treatment of herpes virus infections of the skin or mucous membranes in a mammal subject.

Pharmaceutical formulation comprising 2,3-dimethyl-6-(N,N-dimethylaminoethyl)-6H-indolo-(2,3-B)quinoxaline

Thiol derivatives of general formula (II) have antiviral activity, particularly against influenza virus.  In particular, the compound (4-(2-chloro-4-nitrophenyl)piperazin-1-yl)(4-(2-fluoro-6-methoxyphenyl)-1-methyl-1H-1,2,3-triazol-5-yl)methanone is provided. Methods of preparing the compounds are also described.

Compounds and methods

A compound of formula (I) is useful as an antiviral agent, in particular for the treatment of influenza. A method for preparing the compound of formula (I) and a composition including the compound of formula (I) are described.

Methanethione compounds having antiviral activity

A process for transforming a group &#x3e;C&#x2550;O (I) in a compound into a group &#x3e;C&#x2550;S (II) or into a tautomeric form of group (II) in a reaction giving a thionated reaction product, by use of crystalline PS.2 CHN as a thionating agent. A thionating agent which is crystalline PS.2 CHN.

Thionation process and a thionating agent

A pharmaceutical composition for topical administration including 2,3-dimethyl-6-(N,N-dimethylaminoethyl)-6H-indolo-(2,3-b)quinoxaline (B-220) or a pharmaceutically acceptable salt thereof in a pharmaceutically acceptable carrier. The composition is useful for the treatment of herpes virus infections of the skin or mucous membranes in a mammal subject.

Pharmaceutical formulation for treating herpes virus infection comprising 2,3-dimethyl-6-(N,N-dimethylaminoethyl)-6H-indolo-(2,3-b) quinoxaline

A process for transforming a group &#x3e;C&#x2550;O (I) in a compound into a group &#x3e;C&#x2550;S (II) or into a tautomeric form of group (II) in a reaction giving a thionated reaction product, by use of crystalline PS.2CHN as a thionating agent. A thionating agent which is crystalline PS.2CHN.

Thionating agent

Novel substituted indoloquinoxalines of formula (I wherein The compounds are useful as drugs for preventing and/or treating autoimmune diseases.

Alkyl substituted indoloquinoxalines

A compound of formula (I) wherein Ris selected from H, F, Cl, Br, CF, C-Calkoxy and OH; Ris selected from H and C-Calkyl; n is 1-12; m is O or 1; Y is selected from CH, NR, (NRR)+X, O and S; Rand Rare independently selected from H and C-Calkyl; and X&#x2033; is selected from phannaceutically acceptable anions. A method of preparing the compound, its use as a pharmaceutical, and a method of treatment. 

Compounds and use thereof

Novel substituted indoloquinoxalines of formula wherein

Use of a compound of formula (I), wherein R represents hydrogen or one or several, preferably 1 to 4, similar or different substituents in the positions 1-4 and/or 7-10, selected from halogen, preferably Br, lower alkyl/alkoxy group having not more than 4 carbon atoms, trifluoromethyl group, trichloromethyl group, trichloromethyl group; and in one of the positions 7-10 R can be a hydroxyl group; X is a group&mdash;(CH )n&mdash;R , wherein R represents a nitrogen containing basic residue such as NH ,NHR or NR R , wherein R , R and R independently are lower alkyl or cycloalkyl and n is an integer of from 1 to 4 and R represents hydrogen, lower alkyl/cycloalkyl group having not more than 4 carbon atoms, and the physiologically acceptable addition products of the compounds with acids and halogen adducts, preferably adducts with iodine, iodine monochloride or iodine monobromide, as an agent for protecting tissues, organs and cells in transplantation is described.

Growing community of inventors

Spanga, Sweden

Jan Bergman